Treatment

Check out our comprehensive educational activities here

Jeffrey E. Lancet, MD

What are the current treatment options for older secondary acute myeloid leukemia (sAML) patients with myelodysplasia (MDS)-related changes?

Join Dr. Lancet as he discusses the treatment options for older secondary acute myeloid leukemia patients with myelodysplasia-related changes.

Published on September 15, 2021 in Treatment

Begin

Sandra E. Kurtin, PhD, ANP-C, AOCN©

What is the definition of secondary acute myeloid leukemia (sAML)?

It is important to differentiate between the two subtypes of sAML when deciding how to best treat these patients. In this activity, Dr. Kurtin describes treatments for both subtypes.

Published on September 8, 2021 in Treatment

Begin

Marina Konopleva, MD, PhD

What is the rationale for targeting BCL-2 in AML?

In this activity, Dr. Konopleva explains the rationale for targeting BCL-2 in AML.

Published on August 25, 2021 in Treatment

Begin

Kendra Sweet, MD, MS

How do you determine patient fitness for intensive treatment?

Join Dr. Sweet as she discusses patient profiles and who should be considered fit or unfit for intensive therapy.

Published on August 18, 2021 in Treatment

Begin

Eytan M. Stein, MD

How does the concept of measurable residual disease (MRD) apply to therapy today and moving forward?

In this activity, Dr. Stein describes why MRD negativity is a goal of therapy and how to achieve it in certain patients.

Published on August 11, 2021 in Treatment

Begin

Eytan M. Stein, MD

How does maintenance therapy fit into the framework of AML treatment?

In AML, the role of maintenance therapy has been unclear. In this activity, Dr. Stein reviews data from the QUAZAR study and which patients with AML may benefit from this treatment.

Published on August 2, 2021 in Treatment

Begin

Jeffrey E. Lancet, MD

A Case Study in Secondary AML: Best Practice for Treatment Selection

In this activity, Dr. Lancet discusses choice of therapy for a patient who presents with secondary AML.

This activity is supported by educational grants from Actinium Pharmaceuticals, Bristol-Myers Squibb, and Jazz Pharmaceuticals.

Published on January 20, 2021 in Treatment

Begin

Eunice S. Wang, MD

Is it possible to deliver liposomal daunorubicin and cytarabine on an outpatient basis?

In this activity, Dr. Eunice Wang explains the adverse events associated with liposomal cytarabine and daunorubicin and how to manage them on an outpatient basis.

Published on December 7, 2020 in Treatment

Begin

Eunice S. Wang, MD

What are the key factors you must take into consideration in determining upfront treatment for patients with high-risk, secondary AML?

Dr. Wang describes how she determines upfront therapy for a patient with newly diagnosed secondary AML.

Published on November 30, 2020 in Treatment

Begin

Naval Daver, MD, Jessica K. Altman, MD, Alexander Perl, MD

Expert Opinions on Common Clinical Challenges in AML

In this newsletter, three experts address common clinical challenges practitioners face in AML such as maintenance regimens for FLT3-mutated AML or MRD-eradicating strategies.

Published on October 14, 2020 in Treatment

Begin